Arrowhead Pharmaceuticals Inc ARWR:NASDAQ

Last Price$47.12Cboe Real-Time Last Sale as of 9:36AM ET 8/17/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.51(1.07%)
Bid (Size)$46.50 (100)
Ask (Size)$46.87 (46)
Day Low / High$46.93 - 47.13

View Biotechnology IndustryPeer Comparison as of 08/17/2022


Arrowhead Pharmaceuticals Inc ( NASDAQ )

Price: $47.12
Change: -0.51 (1.07%)
Volume: 6.00
9:36AM ET 8/17/2022

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Mirati Therapeutics Inc ( NASDAQ )

Price: $83.02
Change: -2.36 (2.76%)
Volume: 861.5 K
9:40AM ET 8/17/2022

Denali Therapeutics Inc ( NASDAQ )

Price: $35.94
Change: -0.29 (0.80%)
Volume: 464.1 K
9:42AM ET 8/17/2022

Blueprint Medicines Corp ( NASDAQ )

Price: $53.63
Change: -14.92 (21.77%)
Volume: 252.4 K
9:42AM ET 8/17/2022

Read more news Recent News

Arrowhead Pharmaceuticals Applies for Clearance for ARO-MMP7 Trials
8:17AM ET 8/17/2022 MT Newswires

Arrowhead Pharmaceuticals (ARWR) on Wednesday said it applied for clearance to initiate a phase 1/2a clinical trial of ARO-MMP7, the company's...

--Goldman Sachs Adjusts Price Target on Arrowhead Pharmaceuticals to $65 From $58, Reiterates Buy Rating
9:11AM ET 8/08/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Arrowhead Pharmaceuticals Fiscal Q3 Loss Widens, Revenue Drops; Shares Sink After Hours
4:17PM ET 8/04/2022 MT Newswires

Arrowhead Pharmaceuticals (ARWR) late Thursday reported a fiscal Q3 net loss of $0.68 per diluted share, more than doubling its $0.29 per share loss during...

Arrowhead Pharmaceuticals Says Dosing Under Way in Two Trials of Pulmonary Disease Drug Candidates
9:38AM ET 7/05/2022 MT Newswires

Arrowhead Pharmaceuticals (ARWR) said Tuesday it has started dosing subjects in two phase 1/2a clinical trials of its ARO-MUC5AC and ARO-RAGE...

Company Profile

Business DescriptionArrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA. View company web site for more details
Address177 East Colorado Boulevard
Pasadena, California 91105
Number of Employees116
Recent SEC Filing08/04/202210-Q
President, Chief Executive Officer & DirectorChristopher Richard Anzalone
COO, Secretary & Chief Compliance OfficerPatrick C. O'brien
Chief Financial OfficerKenneth Allen Myszkowski
Chief Medical OfficerJavier San Martin

Company Highlights

Price Open$46.99
Previous Close$47.63
52 Week Range$26.81 - 84.83
Market Capitalization$5.0 B
Shares Outstanding105.8 M
SectorHealth Technology
Next Earnings Announcement11/28/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.48
Beta vs. S&P 500N/A
Revenue$16.1 M
Net Profit Margin-61.59%
Return on Equity-36.48%

Analyst Ratings as of 07/25/2022

Consensus RecommendationConsensus Icon
Powered by Factset